PubMed Health⌕ Search

PubMed · 12271014

Endoplasmic Reticulum Forms a Dynamic Continuum for Lipid Diffusion between Contiguous Soybean Root Cells.

Abstract

Intercellular communication between plant cells for low molecular weight hydrophilic molecules occurs through plasmodesmata. These tubular structures are embedded in the plant cell wall in association with the plasmalemma and endoplasmic reticulum (ER). Transmission electron microscopy has provided strong evidence to support the view that both the ER and plasmalemma are structurally continuous across the wall at these sites. In experiments to be described, the technique of fluorescence redistribution after photobleaching was used to examine the lateral mobility and intercellular transport capability of a number of fluorescent lipid and phospholipid analogs. These probes were shown by confocal fluorescence microscopy to partition in either the ER or plasmalemma. Results from these measurements provide evidence for cell communication between contiguous cells for probes localized predominantly in the ER. In contrast, no detectable intercellular communication was observed for probes residing exclusively in the plasmalemma. It was of particular interest to note that when 1-acyl-2-(N-4-nitrobenzo-2-oxa-l,3-diazole)aminoacylphosphatidylcholine was utilized as a potential reporter molecule for phospholipids in the plasmalemma, it was quickly degraded to 1-acyl-2-(N-4-nitrobenzo-2-oxa-1,3-diazole)aminoacyldiglyceride (NBD-DAG), which then appeared predominantly localized to the ER and nuclear envelope. This endogenously synthesized NBD-DAG was found to be capable of transfer between cells, as was exogenously incorporated NBD-DAG. Results from these investigations provide support for the following conclusions: (1) ER, but apparently not the plasmalemma, can form dynamic communication pathways for lipids across the cell wall between connecting plant cells; (2) the plasmodesmata appear to form a barrier for lipid diffusion through the plasmalemma; and (3) lipid signaling molecules such as diacylglycerol are capable of transfer between contiguous plant cells through the ER. These observations speak to issues of plant cell autonomy for lipid synthesis and mechanisms of intercellular signaling and communication.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

S. Grabski, A. W. De Feijter, M. Schindler. 1993. Endoplasmic Reticulum Forms a Dynamic Continuum for Lipid Diffusion between Contiguous Soybean Root Cells.. https://doi.org/10.1105/tpc.5.1.25

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Effectiveness of high-dose versus standard-dose influenza vaccines against hospitalisation according to frailty risk: a prespecified analysis of the randomised trial DANFLU-2.

BACKGROUND: Frailty is a major risk factor for influenza-related complications and can influence vaccine effectiveness. We aimed to assess the relative vaccine effectiveness (rVE) of high-dose (HD-IIV) versus standard-dose inactivated influenza vaccine (SD-IIV) in older adults aged 65 years or older according to frailty risk. METHODS: This study was a prespecified analysis of DANFLU-2, an open-label, individually randomised trial, conducted in Denmark during three consecutive influenza seasons (2022-23, 2023-24, and 2024-25). Adults aged 65 years or older were randomised (1:1) to the HD-IIV or SD-IIV group. The primary endpoint was hospitalisation for influenza or pneumonia. Frailty was defined according to the validated Hospital Frailty Risk Score (HFRS) based on ICD-10 codes within 10 years before randomisation. Participants were stratified into three HFRS categories, namely low (<5 points), intermediate (5-15 points), and high (>15 points) frailty risk. The rVE of HD-IIV versus SD-IIV against the primary endpoint was assessed across prespecified HFRS categories and treating HFRS as a continuous variable. Pearson's chi-square test was used to compare safety events across frailty risk groups and randomisation groups. FINDINGS: Among 332&#x2009;438 randomised participants (mean age 73&#xb7;7 years [SD 5&#xb7;8]; 161&#x2009;538 [48&#xb7;6%] were female), 276&#x2009;173 (83&#xb7;1%) had low frailty risk, 52&#x2009;395 (15&#xb7;8%) had intermediate frailty risk, and 3861 (1&#xb7;2%) had high frailty risk. The primary endpoint of hospitalisation for influenza or pneumonia occurred in 1424 (0&#xb7;5%) of 276&#x2009;173 participants with low frailty risk, 761 (1&#xb7;5%) of 52&#x2009;395 with intermediate frailty risk, and 163 (4&#xb7;2%) of 3861 with high frailty risk (relative risk [RR] for intermediate vs low frailty risk 2&#xb7;8 [95% CI 2&#xb7;6-3&#xb7;1]; RR for high vs low frailty risk 8&#xb7;2 [7&#xb7;0-9&#xb7;6]). HFRS as a continuous variable significantly modified the effect of HD-IIV versus SD-IIV against the primary endpoint with higher rVE estimates with increasing HFRS (pinteraction=0&#xb7;020). The rVE was 0&#xb7;2% (95% CI -10&#xb7;8 to 10&#xb7;2) among those with low frailty risk, 13&#xb7;1% (-0&#xb7;4 to 24&#xb7;8) among those with intermediate frailty risk, and 19&#xb7;9% (-10&#xb7;3 to 42&#xb7;1) among those with high frailty risk. No significant interaction was observed when HFRS was assessed according to the prespecified categorical frailty groups (pinteraction=0&#xb7;17). The proportion of participants with at least one serious adverse event increased across frailty risk groups (13&#x2009;366 [4&#xb7;8%] of 275&#x2009;795 for low frailty risk, 5475 [10&#xb7;5%] of 52&#x2009;315 for intermediate frailty risk, and 777 [20&#xb7;2%] of 3850 for high frailty risk; p<0&#xb7;0001), with similar proportions of serious adverse events in the HD-IIV and SD-IIV groups for each frailty risk group. INTERPRETATION: Among adults aged 65 years or older in Denmark, frailty risk might modify the effects of HD-IIV versus SD-IIV against hospitalisation for influenza or pneumonia, with higher rVE estimates with increasing frailty risk. These findings might support considering high-dose influenza vaccines for frail older adults. However, effect modification was not evident when frailty was assessed using prespecified categorical subgroups, and subgroup-specific estimates were imprecise, with 95% CIs crossing the null. These results should be considered exploratory, warranting further investigation. FUNDING: The DANFLU-2 trial was funded by Sanofi.

Journal Article↗